More FDA-approved treatments needed for non-melanoma skin cancers

Valencia D. Thomas, MD, MHCM, discusses the remaining unmet needs in the field of non-melanoma skin cancer.

Valencia D. Thomas, MD, MHCM, Professor in the Department of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, discusses the remaining unmet needs in the field of non-melanoma skin cancer.

The most common types of non-melanoma skin cancers are basal cell carcinoma, Merkel cell carcinoma, and squamous cell carcinoma. Although these cancer types have seen many new developments over the past 10 years, there remains a need for more FDA-approved drugs for patients with rare tumor types.

During a session at the 2022 National Comprehensive Cancer Network (NCCN) Annual Meeting, Thomas discussed advanced or aggressive non-melanoma skin cancers that came back after their first treatment as well as those that started in a detection advanced.

While there are various treatment options available for this patient population, including surgical treatments, radiation therapy, and systemic options, Thomas notes that more research needs to focus on treatment that can provide positive opportunities and lead to healing for these patients.

Transcription:

0:08 | Although we have come a long way in the past 10 years, we need to gather more information about the rare tumor type, to have FDA approved drugs for some of these rare tumor types, and to further expand the use of immunotherapy for rare tumors.

0:33 | We use what is currently available to the best of our abilities. As innovative technologies and therapies become more available, we start with what is most common. Then we have to go to what is less common to get the same set of data and information so that we can give the same result to aggressive tumors that may not be as common.

Comments are closed.